Will utilize Manifold’s mDesign drug discovery engine and tissue-targeting shuttle portfolio to create blood-brain barrier shuttles for multiple brain-targeted therapeutic modalities.
Whether you’re a small startup or an established sponsor, Curia’s 10 U.S. facilities can support your small molecule or biologic from curiosity to cure.
CDR111 is a trispecific M-gager, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset.
Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule expertise focusing on oral dosage forms. Adare’s specialized technology platforms provide taste masking, customized release, multiparticulate systems, and patient-centric dosing solutions. With a proven history in drug delivery, Adare’s facilities in the US and Europe have developed and manufactured more than sixty-five products sold by customers worldwide.
